The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBatm Advanced Regulatory News (BVC)

Share Price Information for Batm Advanced (BVC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.65
Bid: 18.40
Ask: 19.65
Change: 0.775 (4.11%)
Spread: 1.25 (6.793%)
Open: 19.65
High: 19.65
Low: 19.65
Prev. Close: 18.875
BVC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Business and Trading Update

25 Jun 2020 07:00

RNS Number : 0037R
BATM Advanced Communications Ld
25 June 2020
 

LEI: 213800FLQUB9J289RU66

25 June 2020

 

BATM Advanced Communications Limited

("BATM" or "the Group")

 

Business and Trading Update

 

BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, provides the following business and trading update.

 

Further to the Group's announcement of 30 April 2020, in which BATM provided an update on the impact of the COVID-19 outbreak on its two divisions, the Group is pleased to report that the Bio-Medical division has performed exceptionally well throughout the first half of the year. This has been based on several initiatives, such as the sale of antigen and antibody testing kits to health authorities in various countries as well as the sale of critical care ventilators. The Networking & Cyber division was only slightly impacted by COVID-19 in Q1 2020, with sales remaining higher than in Q1 2019. As previously noted, there was some slowdown in this division in the early part of Q2 2020 as lockdowns commenced across the globe. However, since late May 2020 this division has seen a return towards normal trading as some customers who had temporarily postponed certain projects have commenced discussions and, as lockdown measures are increasingly lifted, the division is recommencing the activities it could not perform previously due to the restrictions on travelling to the premise of a customer or a supplier. While it is still early days, this gives confidence to the management team that the full year impact of the pandemic on the Networking & Cyber division will now be minimal.

 

As a result of the considerable growth in the Bio-Medical division, which has more than offset any loss of revenues in the Networking & Cyber division, BATM now expects to report a substantial increase in FY 2020 revenues, at least 25% higher than FY 2019 and materially higher than market expectations. It also expects to report EBITDA significantly ahead of market expectations.

 

The growth in the Bio-Medical division is due to the substantial investment the Group has made in recent years to build a best-in-class diagnostics platform. This division is able to quickly provide solutions that include diagnostic kits for any new pathogen that appears and devices including diagnostic instruments, ventilators and pathogenic waste disposal units. As a result, this division was able to respond rapidly when it was first alerted to the potential outbreak of COVID-19.

 

In the first half, the Group was able to launch a new diagnostics antigen molecular (RTPCR) test kit to detect COVID-19 that underwent clinical verification and evaluation by leading universities and hospitals in February and received certification at the end of March 2020. Additionally, in May 2020, the Group launched ELISA lab serological test kits that diagnose if a patient has had COVID-19 by detecting antibodies against it present in their blood. Production and sales of both kits have been ramping up and the Group has shipped several hundred thousand test kits with a backlog of over a million orders still to be delivered.

 

In addition to the sales of the newly launched kits (reagents), the Group has received increased demand for its instruments (readers). During the summer months, the Group is adding further production capacity for its reagents and instruments to satisfy potential orders from the continued interest the Group is receiving from around the world.

 

As previously announced, the Group is in the process of developing, in partnership with Novamed, a rapid COVID-19 diagnostics antigen test kit for home-use, which is expected to be completed in the coming months with sales commencing in the fourth quarter of the year. The Group is also in the advanced stages of development of unique solutions that are expected to be commercially released in September 2020 in anticipation of a second wave of several respiratory pathogens, particularly flu and coronavirus.

 

Finally, during the first half of 2020, the Group received an order of €29m (c. $31m) from a European government to provide 1,000 critical care ventilators to support their response to COVID-19. The Group has made significant progress towards completing the delivery of the contract on time.

 

BATM is also pleased to announce that it has attracted significant talent into the business to manage the increased interest that is being received. In June 2020, it appointed former Roche Executive, Jeremy Moss, as its Global Head of Point of Care. Mr Moss, who will operate from the UK, has served various senior roles at Roche over the past 22 years, most recently Head of Management Centre European Agents (MCEA) and Senior Vice President Roche Centralised and Point of Care Solutions.

 

The Group continues to work hard to ensure its employees are fully supported in remaining safe, well and able to work. The Board believes that, with the actions taken to date in response to the pandemic along with the further work to be undertaken to achieve the Group's strategic objectives in 2020, BATM will continue to deliver shareholder value.

 

BATM will provide further details in its Interim Results announcement in August 2020.

 

Enquiries:

BATM Advanced Communications

Dr Zvi Marom, Chief Executive Officer

+972 9866 2525

Moti Nagar, Chief Financial Officer

Shore Capital

Mark Percy, Anita Ghanekar, James Thomas (Corporate Advisory)

Henry Willcocks (Corporate Broking)

+44 20 7408 4050 

Luther Pendragon

Harry Chathli, Claire Norbury

+44 20 7618 9100

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTKZLFLBQLLBBB
Date   Source Headline
6th Nov 20139:56 amRNSHolding(s) in Company
15th Oct 20137:00 amRNSInterim Management Statement
9th Oct 20131:35 pmRNSHolding(s) in Company
8th Oct 20139:47 amRNSBATM to join three Tel-Aviv stock exchange indexes
9th Sep 20138:32 amRNSHolding(s) in Company
22nd Aug 20139:59 amRNSDirectorate Change
16th Aug 20133:51 pmRNSResult of AGM
12th Aug 20137:00 amRNSInterim results
2nd Aug 20134:35 pmRNSPrice Monitoring Extension
1st Aug 20138:41 amRNSHolding(s) in Company
31st Jul 201310:48 amRNSNotice of Results
25th Jul 20133:45 pmRNSNotice of AGM
12th Jul 20137:00 amRNSFinancial Closing of Consortium Agreement
10th Jul 201310:14 amRNSHolding(s) in Company
17th Jun 201311:00 amRNSBATM Wins Israel Infrastructure Contract
14th Jun 20137:00 amRNSCapital Markets Day
11th Jun 20134:40 pmRNSSecond Price Monitoring Extn
11th Jun 20134:35 pmRNSPrice Monitoring Extension
10th Jun 20134:40 pmRNSSecond Price Monitoring Extn
10th Jun 20134:35 pmRNSPrice Monitoring Extension
6th Jun 201312:42 pmRNSDirector Share Purchase
6th Jun 201312:35 pmRNSHolding(s) in Company
6th Jun 20137:00 amRNSTrading Statement
21st May 20137:00 amRNSHolding(s) in Company
8th May 20133:25 pmRNSHolding(s) in Company
2nd May 20137:00 amRNSInterim Management Statement
30th Apr 201312:00 pmRNSAnnual Financial Report
25th Mar 20137:00 amRNSBATM wins contract in South Korea
18th Feb 201312:19 pmRNSHolding(s) in Company
18th Feb 20137:00 amRNSFinal Results
13th Feb 20137:00 amRNSNotice of Results
30th Jan 20132:00 pmRNSBATM awarded Carrier Ethernet 2.0 certification
22nd Jan 20138:08 amRNSHolding(s) in Company
18th Jan 20137:00 amRNSInvestor Site Visit
8th Jan 201311:19 amRNSHolding(s) in Company
31st Dec 201212:48 pmRNSTotal Voting Rights
21st Dec 20123:11 pmRNSHolding(s) in Company
30th Nov 20128:47 amRNSHolding(s) in Company
5th Nov 20127:00 amRNSInterim Management Statement
17th Oct 20127:00 amRNSNew client wins for BATM
10th Oct 20124:03 pmRNSDirector/PDMR Shareholding
5th Oct 20127:00 amRNSTotal Voting Rights
21st Sep 20127:00 amRNSHolding(s) in Company
11th Sep 20127:00 amRNSBATM to dual list on TASE
6th Sep 20129:56 amRNSHolding(s) in Company
22nd Aug 20124:40 pmRNSSecond Price Monitoring Extn
22nd Aug 20124:35 pmRNSPrice Monitoring Extension
16th Aug 20127:00 amRNSInterim Results
8th Aug 20122:49 pmRNSElection of Home State
24th Jul 20127:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.